XERISOL
Live / Registered — Registered (as of 05 Nov 2024)
What this means for you
Registered since 05 Nov 2024. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 90359499
- Registration number
- 7559452
- Mark type
- Stylized text
- Filed
- 04 Dec 2020
- Published for opposition
- 29 Jun 2021
- Registered
- 05 Nov 2024
- Attorney of record
- Tracy-Gene G. Durkin
Goods and services
- Class 042 — Scientific and technological services: Pharmaceutical research and development; pharmaceutical drug formulation and development services; providing information on drug technology platforms for the formulation and development of drugs and biologics
Owner
- Xeris Pharmaceuticals, Inc., Chicago, IL, US
- Xeris Pharmaceuticals, Inc., Chicago, IL, US
- Xeris Pharmaceuticals, Inc., Chicago, IL, US
Prosecution history
- 05 Nov 2024 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 05 Nov 2024 — REGISTERED-PRINCIPAL REGISTER
- 03 Oct 2024 — NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
- 03 Oct 2024 — ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
- 02 Oct 2024 — STATEMENT OF USE PROCESSING COMPLETE
- 01 Aug 2024 — USE AMENDMENT FILED
- 02 Oct 2024 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 01 Aug 2024 — TEAS STATEMENT OF USE RECEIVED
- 14 Feb 2024 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 13 Feb 2024 — SOU EXTENSION 5 GRANTED
- 13 Feb 2024 — SOU EXTENSION 5 FILED
- 13 Feb 2024 — SOU TEAS EXTENSION RECEIVED
- 25 Aug 2023 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 23 Aug 2023 — SOU EXTENSION 4 GRANTED
- 23 Aug 2023 — SOU EXTENSION 4 FILED